Zhang Guodong, Chi Nannan, Lu Qingfeng, Zhu Dandan, Zhuang Yongzhi
Department of Oncology, Daqing Oilfield General Hospital, Daqing, Heilongjiang, P.R. China.
Department of Gastroenterology, the First Affiliate Hospital of Jiamusi University, Jiamusi, Heilongjiang, P.R. China.
Cancer Biother Radiopharm. 2020 Feb;35(1):77-81. doi: 10.1089/cbr.2019.2991. Epub 2019 Nov 8.
Long noncoding RNA (lncRNA) papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3) inhibits several types of cancer, whereas its role in gastric cancer is unknown. From May 2010 to May 2015, this study included 68 (36 males and 32 females, 35-69 years, 48.3 ± 7.1 years) gastric cancer patients and 60 healthy volunteers (32 males and 28 females, 34-67 years, 48.8 ± 6.5 years). Transient transfections, QPCR, CCK-8, transwell cell migration, and invasion assay were used for carrying out the research. The authors found that plasma PTCSC3 was downregulated in gastric cancer patients. Downregulation of PTCSC3 distinguished early stage gastric cancer patients from healthy controls. LncRNA PTCSC3 expression levels were increased on the day of discharge in gastric cancer patients compared with pretreatment levels. During follow-up, patients with low plasma levels of PTCSC3 showed a significantly lower overall survival rate. PTCSC3 negatively regulated proliferation, invasion, and migration of gastric cancer cells. Therefore, lncRNA PTCSC3 may serve as a biomarker for the treatment and prognosis of gastric cancer.
长链非编码RNA（lncRNA）甲状腺乳头状癌易感候选基因3（PTCSC3）可抑制多种类型的癌症，但其在胃癌中的作用尚不清楚。2010年5月至2015年5月，本研究纳入了68例（36例男性和32例女性，年龄35 - 69岁，平均48.3±7.1岁）胃癌患者和60名健康志愿者（32例男性和28例女性，年龄34 - 67岁，平均48.8±6.5岁）。采用瞬时转染、QPCR、CCK - 8、transwell细胞迁移和侵袭实验进行研究。作者发现，胃癌患者血浆PTCSC3表达下调。PTCSC3的下调可区分早期胃癌患者与健康对照。与治疗前水平相比，胃癌患者出院当天lncRNA PTCSC3表达水平升高。随访期间，血浆PTCSC3水平低的患者总生存率显著降低。PTCSC3对胃癌细胞的增殖、侵袭和迁移具有负向调控作用。因此，lncRNA PTCSC3可能作为胃癌治疗和预后的生物标志物。
